The Warning Letter Brief

 FDA Regulatory Intelligence
Friday, October 30, 2026
Independent · not affiliated with or endorsed by the FDA. AI-generated with human-in-the-loop review, from public FDA Warning Letters — every letter links to its FDA source; verify before acting.
At a glance
11 new warning letters + 2 carried-over workups (1 critical) · 5 critical · 15 Stop-Use red flags in this week's letters.
5 Critical2 High4 listed (not risk-graded)Also: 2 carried-over workups (1 critical)7 full workups below
What matters this week
Your one move this week
Pull your last 10 finished-product releases and confirm each had assay, impurity, and microbial data recorded before shipping.
Floor-action deep dives — detailed below
Also in this issue — earlier letters, detailed below
This week's floor actions — one page for your shift leads
One action per letter, pulled from the full workups (the Table of Contents maps every letter). Print and hand out.
Start here: Pull your last 10 finished-product releases and confirm each had assay, impurity, and microbial data recorded before shipping.
This Week's Read
An editor's read across this week's letters — what FDA is prioritizing, and the one move that matters.

FDA is pressing on basic proof of safety and quality. Three drug makers skipped core testing or failed to investigate contamination controls. A separate theme hits devices: four firms sold products with no approval or outside their cleared use. The drug testing gaps touch manufacturers; the marketing-claim letters touch device marketers. The top action: prove every batch and ingredient was tested before release.

Patterns & sweeps
Unapproved or off-label devices 2 letters
FDA cited these device firms for selling or marketing products without the required clearance. Each lacked a valid PMA or 510(k), or made claims beyond its cleared use.
So what: Applies to device marketers and makers selling modified or newly-indicated products; a cleared device maker who stays within its indication can ignore this.
Chirp Innovations, LLC · Pro-Optics, LLC
How to read this brief
What this covers. Built from the FDA warning letters posted this week — this issue covers the drugs & biologics, food and medical devices centers, plus 2 full workups of letters listed in an earlier issue (marked “Carried over”). The data-integrity and quality-system lessons transfer to any dosage form — each detailed letter includes an oral-solid-dose and a topical/liquid translation. Biologics-specific risks (single-use systems, cold chain, comparability, viral safety, live-cell handling) are out of current scope.
Severity ranks (per letter)
  • Critical Goes straight to patient safety or the integrity of FDA's evidence: a sterility failure, data integrity/falsification, a quality-unit breakdown, an active import alert, or a marketed product shown defective by actual test results (FDA's or the firm's own) — not the routine “adulterated” wording the law attaches to every cGMP letter.
  • High A serious, systemic CGMP/QMSR gap (unvalidated process, no supplier qualification, complaint/CAPA failure) that is still contained in scope — no specific patient or lot shown harmed yet.
  • Moderate A real but bounded deficiency — usually procedural, documentation, or a one-time lapse — that signals weak control without immediate product or patient exposure.
  • Low An isolated administrative or labeling-level issue, with no shown impact on product quality or patient safety.
  • Listed Not risk-graded. A letter outside manufacturing/quality scope (marketing, labeling, or unapproved-drug claims only) or beyond this run's deep-dive budget — indexed in full but not deep-read. It appears ONLY as its Table of Contents line, with a link to the source FDA letter; it does not get its own page below.
  • Carried over A letter already listed in an earlier issue whose full workup was not ready then. Its full workup appears in this issue; it is not counted again as a new letter.
These ranks reflect FDA's enforcement severity — not the risk to YOUR site. Calibrate each one to your own products, patients, and risk tolerance. When your judgment differs from ours, move the item up a level, never down.
KPI severity (what to do)
  • Stop-Use Halt and quarantine now. The risk is to product safety or distribution, not paperwork.
  • Escalate Raise to the Quality Review Board for a decision. Serious, but not an immediate halt.
  • Monitor Trend it over time. Watch the signal; no immediate action needed.
Other terms
  • Leading A measure that warns you before a gap happens (the kind we prefer). Lagging only confirms a problem after the fact.
  • Quality Review Board Your quality-governance forum (QRB), where escalated issues are decided and owned.
  • Daily Production Meeting Your daily production huddle, where fast, daily-cadence checks are run on the floor.
Confidence tags (on interpretation)
  • FDA-stated The FDA letter says this directly — it is a fact, not our interpretation.
  • Strong inference Very likely but NOT stated by FDA — our reading of the facts (roughly 60–80% sure).
  • Plausible A real possibility, not stated by FDA (roughly 30–60% sure). Confirm before you rely on it.
  • Speculative A weaker possibility (under ~30%), flagged so you can check — not a conclusion.
Table of Contents
All 13 letters in this issue · grouped by sector · every entry links to the FDA-published letter — nothing in this issue is dropped. The manufacturing- and quality-system letters — those citing CGMP, QSR/QMSR, sterility or aseptic processing, data integrity, or a food-safety program (FSVP, preventive controls, HACCP) — earn a full floor-action workup. Where several letters cite near-identical findings, they are analyzed together and presented as one sweep summary rather than repeating the same workup; every letter is still listed and linked. Letters citing only marketing, labeling, or unapproved-drug claims are listed in full but not deep-read — the call is made on the letter's own text, so a letter whose FDA subject line reads “unapproved drugs” still earns a workup when the text cites CGMP or sanitation findings.
Drugs & Biologics
3 letters detailed in full · 4 indexed
Critical
Northland Nuclear Medicine, LLC
Drug · Bismarck, ND · Center for Drug Evaluation and Research (CDER) · Posted 10/27/2026 · Issued 10/22/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA found PET drug products adulterated under FD&C Act section 501(a)(2)(B); the June 2026 FDA 483 response was inadequate.
  • Over 100 ISO 5 microbial recoveries occurred from March 2024 to April 2026; more than 90 had no formal species identification.
  • EM contact plates were stored with a redacted sporicidal solution, risking false-negative EM results and unreliable historical data.
  • The firm lowered its radiochemical yield limit rather than correcting the root cause; Incident Report NNM 2025 08 called it 'an ongoing issue for more than a year.'
  • FDA cited repeat violations — similar CGMP issues were discussed at a December 2023 regulatory meeting — and stated executive management oversight is inadequate.
✅ Here's what you need to check for
  • ☐ Do your ISO 5 microbial isolates get formally identified to genus and species level — with records — within your EM program, every time?
    If you can't confirm this: Quarantine any batches released without complete isolate identification since your last confirmed compliant EM cycle. Open a CAPA immediately. Assign a QA owner and a 30-day deadline to establish a written procedure for formal identification of all ISO 5 recoveries.
  • ☐ Are your EM contact plates stored and handled in a location completely free of disinfectants or sporicidal agents — at all times, before and after sampling?
    If you can't confirm this: Hold EM results from any sampling period where plates may have been exposed to disinfectant. Conduct a retrospective review of all affected EM data and past batch release decisions. Update storage and handling SOPs before resuming routine sampling.
  • ☐ Do your smoke studies include dynamic evaluations of aseptic operations — with product/component transfers and real interventions — under representative conditions?
    If you can't confirm this: Stop relying on static or mock-only smoke studies for sterility assurance. Schedule dynamic smoke studies with a qualified consultant before your next batch release cycle. Document specific interventions evaluated.
  • ☐ When a process parameter (such as yield or bioburden count) repeatedly fails your action limit, does your CAPA system require a documented root cause — not just a limit adjustment — before the CAPA is closed?
    If you can't confirm this: Open a CAPA audit. Identify all CAPAs closed in the past two years without a documented root cause. Reopen any where the only action was a limit change. Assign a QA director as owner with a 45-day deadline for root-cause reanalysis.
  • ☐ Does your QU independently review all batch records, EM trends, and CAPA effectiveness checks before batch disposition — with documented, dated sign-off?
    If you can't confirm this: Suspend batch disposition until a documented QU review process is in place. Engage a qualified CGMP consultant to assess QU authority and resource adequacy. Name one QU director as accountable owner with a 15-business-day initial assessment deadline.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): Confirm your EM program for tablet/capsule manufacturing areas formally identifies microbial isolates to genus level when action limits are exceeded — not just colony counts. Confirm CAPAs for recurring OOL results require documented root cause before closure; limit adjustments without root cause are not acceptable. Check your SOP against 21 CFR 211.192 for investigation requirements.
  • Topical / semisolid / liquid: Confirm EM plates and bioburden samples are never stored near preservatives, sanitizers, or other antimicrobial agents at any point in the sample chain. Confirm your purified-water loop sanitization records and bioburden/endotoxin results for each batch are reviewed by QU before release. Verify your objectionable-organism testing covers your specific product family per USP <61>/<62>. Rule: 21 CFR 211.192.
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • ISO 5 critical aseptic area — at EM plate collection, handling, transport, and incubation steps — Observe whether EM plates are set down, stored, or transported near any spray bottle, disinfectant container, or surface wetted with disinfectant at any point before or after sampling. Confirm each plate has a unique label and that a handler signature and time-stamp are recorded at each custody transfer. Look for any plate left unattended without a log entry.
  • Microbiology lab — during plate reading and identification recording — Watch a live plate reading. Confirm the technician records a formal genus/species identification, not a shorthand note like 'resembles previous.' Confirm the LIMS or logbook entry includes a date, technician name, and result — not a blank or a transcribed tally. Check whether any plates from the current EM cycle lack a formal identification entry.
  • LAFW and surrounding ISO 7 cleanroom — during a live aseptic manufacturing run — Observe actual operator interventions in the ISO 5 zone. Check whether any operator reaches into the critical zone in a way not covered by a dynamic smoke study. Confirm the disinfection of all redacted equipment surfaces is performed before the run starts, using a written procedure — not verbal instruction. Note whether the disinfection step is documented with a date, time, and operator signature.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your QC / Micro Lab supervisor
  • Ask: When you read an ISO 5 plate and see a colony, what exactly do you write in the log? Walk me through your last entry.
    🚩 Flag if you hear: Operator writes 'resembles previous,' leaves species blank, or has no written procedure to follow for identification.
    → Then: Hold affected EM results; tell QA on call; open a deviation today.
  • Ask: Where do you put EM plates after you collect them from the cleanroom, before you put them in the incubator? Sterile / aseptic filling only
    🚩 Flag if you hear: Operator places plates near a spray bottle, disinfectant container, or any wetted surface at any point.
    → Then: Quarantine all plates from that EM run; tell QA on call; open a deviation today.
Hand to your Production / Aseptic Filling supervisor
  • Ask: Before you start today's run, what steps do you take to disinfect the equipment surfaces in the ISO 5 area? Can you show me the written procedure? Sterile / aseptic filling only
    🚩 Flag if you hear: Operator cannot produce a written procedure or disinfection is done from memory without a documented step in the batch record.
    → Then: Stop the run; tell QA on call; open a deviation today.
Hand to your QA supervisor
  • Ask: When a yield result falls below our action limit, what triggers an investigation — and who decides if we investigate or just adjust the limit?
    🚩 Flag if you hear: Operator says limit changes are decided without a formal investigation or QU sign-off, or that investigations are not always opened for limit exceedances.
    → Then: Hold affected batches; tell QA on call; open a CAPA today.
  • Ask: When was the last CAPA for an EM or yield issue closed? Was an effectiveness check done — and who signed it?
    🚩 Flag if you hear: Operator cannot name the effectiveness check reviewer, or says it was marked 'No' with no follow-up action recorded.
    → Then: Reopen the CAPA; tell QA on call; schedule root-cause review within 5 business days.
💡 Things you may not have thought of
  • False-negative EM data may have masked recurring contamination for months, making historical batch release risk-assessment impossible without independent culture re-examination. Strong inference
  • Lowering a yield action limit resets the CAPA trigger, hiding a failing process from QU oversight metrics — a self-reinforcing gap that routine audits can miss. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use ISO 5 isolate formal ID rate — 100% required — Flag if: Any ISO 5 isolate not formally identified to genus/species within 5 business days of recovery. Daily Production Meeting
  • Stop-Use EM plate sporicidal exposure events — zero tolerance — Flag if: Any plate with documented or suspected sporicidal/disinfectant contact at any point in the EM workflow. Daily Production Meeting
  • Stop-Use Batches released with incomplete QU records — zero — Flag if: Any released batch missing one or more required QU disposition record elements. Daily Production Meeting
  • Stop-Use Aseptic intervention types covered by dynamic smoke study — 100% — Flag if: Any intervention type not yet covered by a dynamic smoke study under representative conditions, or any new intervention added without a new dynamic study. Quality Review Board
  • Escalate CAPA effectiveness check pass rate — 100% at original due date — Flag if: Any CAPA effectiveness check marked 'No,' deferred past original due date, or closed via limit adjustment without root cause. Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • Environmental Monitoring Program SOP: Confirm the SOP requires formal microbial identification to genus and species level for every ISO 5 recovery, with a named identification method and a maximum time limit from collection to result. (21 CFR 212.20(d))
  • Microbiological Sampling Media Handling and Chain-of-Custody SOP: Confirm the SOP prohibits storage or transport of EM plates near any disinfectant or sporicidal agent, and requires unique plate labeling, time-stamped handler signatures at each custody step, and digital photo documentation. (21 CFR 212.30(b))
  • Aseptic Area Cleaning and Disinfection SOP (for all ISO-classified equipment surfaces): Confirm the SOP includes a written, step-by-step disinfection procedure for all equipment surfaces in the ISO 5 area, specifying disinfectant identity, concentration, contact time, frequency, and required documentation before each manufacturing run. (21 CFR 212.30(b))
  • CAPA and Investigation Procedure SOP: Confirm the SOP requires a documented root-cause finding before CAPA closure, prohibits closing a CAPA by adjusting an action limit without root cause, and mandates an independent effectiveness check at the original CAPA closure date. (21 CFR 212.20(d))
Critical
Sanrace Biotechnology Co., Ltd.
Drug · Lanxi, Jinhua, Zhejiang Province, China · Center for Drug Evaluation and Research (CDER) · Posted 10/27/2026 · Issued 10/22/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA placed all Sanrace drugs on Import Alert 66-40 on September 21, 2026, blocking US entry.
  • FDA stated the redacted contaminant has caused lethal poisoning incidents in humans worldwide.
  • The firm admitted it has no process validation procedures or completed validation studies.
  • The QU failed to ensure adequate monitoring, component testing, and complete stability testing.
  • FDA recommends a qualified CGMP consultant and six-system audit before resuming US market activity.
✅ Here's what you need to check for
  • ☐ Do you perform per-lot, per-shipment identity testing on every incoming component that FDA or USP designates as high-risk for hazardous impurities — using the USP identification test, not just a certificate of analysis?
    If you can't confirm this: Quarantine all untested lots of any high-risk component now. Do not release them to manufacturing. Add per-lot USP identification testing before the next release. Open a CAPA with your QA director as owner and a 30-day due date.
  • ☐ Does your firm have written, approved process validation procedures AND completed process qualification studies for every commercial drug product you manufacture?
    If you can't confirm this: Stop commercial distribution of any product lacking a completed process qualification study. Engage a process-validation specialist. Draft a validation master plan within 30 days and set a qualification schedule before resuming distribution.
  • ☐ Does your ongoing stability program include all required attributes — viscosity, pH, assay, and microbiological testing — tested at each time point for every marketed product?
    If you can't confirm this: Pull your current stability protocols and compare them against USP and your registered specifications. For any missing attribute, place the affected product on hold and initiate a risk assessment within 14 days. Update protocols immediately.
  • ☐ Does your quality unit have written authority to approve or reject all components, in-process materials, and finished products — and does it actually exercise that authority before each release?
    If you can't confirm this: Suspend releases until you can verify QU sign-off exists in your records. Rewrite your QU authority SOP to name specific approval steps, assign a QU director, and conduct a lookback of recent releases within 60 days.
  • ☐ Is your facility currently under an FDA import alert, or have you received a 704(a)(4) records request in the past 24 months?
    If you can't confirm this: If yes, treat your compliance posture as under active FDA scrutiny. Engage a qualified CGMP consultant immediately. Do not ship to the US market until you have confirmed your remediation plan addresses all cited violations.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): For high-risk excipients used in OSD (binders, fillers, coatings), confirm your incoming testing SOP requires a per-lot in-house identity test — not just CoA review. Confirm identity test methods are listed in your specification. Rule: 21 CFR 211.84(d)(1).
  • Topical / semisolid / liquid: For aqueous-base products, confirm your incoming testing of each high-risk solvent or humectant includes a per-lot identity test covering hazardous impurity limits. Also confirm your stability protocol includes viscosity, pH, microbial limits (USP <61>/<62>), and preservative efficacy at each time point. Rule: 21 CFR 211.84(d)(1); 21 CFR 211.166(a).
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • Incoming materials receiving and sampling area — Watch whether staff pull per-container samples from every lot of every high-risk component (defined as any component FDA or USP flags for hazardous impurity testing). Check whether USP identification tests — not just certificate-of-analysis review — are completed and recorded before the lot is released to manufacturing.
  • Quality unit laboratory and batch-release area — Watch whether QU staff review and sign off on component test results, stability data, and in-process results before releasing any batch. Look for signed QU approval records on batch records. Check whether stability samples are pulled on schedule and tested for all required attributes (viscosity, pH, assay, microbiology).
  • Manufacturing floor — any active production line — Ask to see the process validation record for the product currently being made. Confirm a completed process qualification study exists. If staff cannot produce one, this is a direct gap. Watch whether batch records reference validated process parameters and whether any in-process monitoring is performed.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your Warehouse / Materials supervisor
  • Ask: When a new shipment of any ingredient comes in, what testing do we do before it goes to manufacturing? Do we test every container in the lot, or just review the supplier's paperwork?
    🚩 Flag if you hear: Operator says they rely on the certificate of analysis without running an in-house USP identity test per lot.
    → Then: Hold the component lot now; tell QA on call; open a deviation today.
Hand to your QC / Chemistry Lab supervisor
  • Ask: If a stability time point is due this month, what attributes are you testing? Walk me through the list. What happens if viscosity or pH is not in your current protocol?
    🚩 Flag if you hear: Operator cannot name all required stability attributes, or says viscosity, pH, assay, or micro testing is not in the current protocol.
    → Then: Hold the affected stability station; tell QA on call; open a deviation today.
Hand to your Production / Manufacturing supervisor
  • Ask: When we start making a batch, is there a validation report we can point to that says this process is approved for commercial manufacturing? Where is it kept?
    🚩 Flag if you hear: Operator cannot locate a completed process qualification study or validation report for the current product.
    → Then: Pause the batch; tell QA on call; open a deviation today.
Hand to your QA supervisor
  • Ask: Before a batch is released, who signs off? Can you show me the last three batch records with QU approval signatures? Is there any batch that shipped without a QU signature?
    🚩 Flag if you hear: QU signature is missing on any batch record, or staff describe an informal or verbal approval process.
    → Then: Hold all unsigned batches now; tell QA on call; open a deviation today.
💡 Things you may not have thought of
  • A 704(a)(4) records-only review can trigger an import alert — a physical inspection is not required for FDA to act. Strong inference
  • Admitting in a written response that no validation procedures exist removes FDA's burden to prove the gap — it becomes an uncontested fact in any enforcement proceeding. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use Per-lot USP identity test rate for high-risk components — Flag if: Any high-risk component lot released to manufacturing without a completed per-container USP identity test result on file. Daily Production Meeting
  • Stop-Use Commercial products with completed process qualification — Flag if: Any commercial product identified without a completed process qualification report signed before first distribution. Quality Review Board
  • Stop-Use QU-signed batch release rate — Flag if: Any batch released without a QU-signed approval on the batch record. Daily Production Meeting
  • Escalate Stability time-point completion rate (all attributes) — Flag if: Any stability time point overdue by more than 7 days or missing any required attribute at the original due date. Quality Review Board
  • Escalate Warning-letter CAPA effectiveness check rate at 90/180 days — Flag if: Any CAPA that does not have a documented effectiveness check result by day 90, or that fails its effectiveness check at day 180. Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • Incoming Component Testing SOP: Confirm the SOP requires per-lot, per-container identity testing for every high-risk component using the applicable USP identification test — not certificate-of-analysis review alone. (21 CFR 211.84(d)(1))
  • Process Validation Master Plan or Procedure: Confirm the SOP defines when process qualification studies must be completed before commercial distribution and requires written protocols and reports for each significant process stage. (21 CFR 211.100(a))
  • Ongoing Stability Program SOP: Confirm the SOP lists all required stability-indicating attributes — including viscosity, pH, assay, and microbiological testing — for each product family and specifies testing intervals across the full shelf-life. (21 CFR 211.166(a))
  • Quality Unit Authority and Batch Release SOP: Confirm the SOP names the QU as the sole authority to approve or reject components, in-process materials, and finished drug products, and requires a QU signature on every batch record before release. (21 CFR 211.22(a))
Critical
TSP Solutions Pte. Ltd.
Drug · Singapore, Singapore · Center for Drug Evaluation and Research (CDER) · Posted 10/27/2026 · Issued 10/22/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA placed all TSP Solutions drugs on Import Alert 66-40 on August 14, 2026 — U.S. imports are currently blocked.
  • FDA found the firm released OTC sunscreen products with no active-ingredient assay, no impurity testing, and no microbial testing.
  • FDA found the firm accepted supplier COAs without any independent component identity testing or supplier validation.
  • FDA characterized the firm's quality systems as inadequate, citing failures in equipment qualification, lab controls, and stability.
  • FDA recommends a qualified CGMP consultant conduct a six-system audit before the firm pursues compliance resolution.
✅ Here's what you need to check for
  • ☐ Does your site perform a specific active-ingredient assay on every finished batch before release — and is the result documented in the batch record?
    If you can't confirm this: Place all unreleased batches on hold immediately. Open a CAPA with QA as owner and a 30-day due date to establish a validated assay method and update the batch-release procedure.
  • ☐ Does your site perform at least one identity test on every incoming component lot — not just review the supplier's COA?
    If you can't confirm this: Quarantine all component lots received without in-house identity testing. Begin per-lot identity testing before any quarantined material is used in production. Assign QC lab manager as owner with a 15-day start date.
  • ☐ Has your site validated your component suppliers by independently testing their materials at defined intervals — and do you have data to show it?
    If you can't confirm this: Conduct a retrospective review of all active suppliers. For any supplier without validation data, treat their components as unqualified. Do not release product made from unvalidated components until supplier reliability is established.
  • ☐ Does your site have an active, documented stability program with samples on study for every marketed product?
    If you can't confirm this: Open a deviation. Assign QA to build a stability protocol and place retained samples on study within 30 days. Report status to site leadership weekly until samples are on study.
  • ☐ Does your quality unit have documented authority — and a record showing it exercises that authority — to approve or reject each batch before release?
    If you can't confirm this: Do not release product until QU authority is documented in SOPs and a qualified QU representative signs each batch disposition. Escalate to site director if QU staffing is insufficient to perform this function.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): Confirm every OSD batch has an in-house potency assay (HPLC or equivalent) AND a dissolution result in the batch record before release — not just a supplier COA. Verify against your specification sheet. Rule: 21 CFR 211.165(a).
  • Topical / semisolid / liquid: Confirm finished-product testing includes microbial limits (USP <61>/<62>), preservative-efficacy testing, and an in-house active-ingredient assay before release. Relying on the filler's or supplier's COA alone does not satisfy this requirement. Rule: 21 CFR 211.165(b).
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • QC laboratory — incoming-component staging and testing area — Components sitting in 'Released' or 'Approved' status without any lab worksheet, instrument printout, or LIMS entry showing an in-house identity test was run. A COA stapled to the component package with no in-house test record is the gap.
  • Batch-record review station or QU release desk — Completed batch records that have a COA from a contract lab but no in-house assay result, no impurity result, and no microbiological test result in the file before the lot-disposition signature line is signed.
  • Stability storage chambers and the QA stability binder or system — Products with no samples on pull schedule, expired pull dates that were never executed, or stability protocols that exist on paper but show no actual time-point results logged in the past 12 months.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your QC / Chemistry Lab supervisor
  • Ask: When a batch is ready to release, what tests do you run yourself in this lab before it ships? Walk me through the last batch you released.
    🚩 Flag if you hear: Operator says they check the supplier's COA or a contract lab's report — but does not describe running an in-house assay themselves.
    → Then: Hold the batch now; tell QA on call; open a deviation today.
  • Ask: For the suppliers we buy active ingredients from — have we ever run our own tests to check whether their COA numbers are accurate? What did we find?
    🚩 Flag if you hear: Lab staff say they have never independently tested a supplier's material against the COA, or cannot recall the last time it was done.
    → Then: Hold components from that supplier now; tell QA on call; open a deviation today.
Hand to your Warehouse / Materials supervisor
  • Ask: When a new drum or bag of raw material arrives, what do you do with it before it goes to the lab? Has any material ever been used in production before the lab cleared it?
    🚩 Flag if you hear: Operator says materials sometimes move to production after just checking the paperwork, without waiting for a lab test result.
    → Then: Hold the affected material now; tell QA on call; open a deviation today.
Hand to your QA supervisor
  • Ask: For each product we sell, do we have samples sitting in stability storage right now with a pull schedule that is current? When did we last pull and test a stability sample?
    🚩 Flag if you hear: QA cannot name the last pull date or says no samples are currently on study for one or more marketed products.
    → Then: Escalate to QU Director today; open a deviation; do not launch new products until program is active.
💡 Things you may not have thought of
  • Retaining samples does not equal testing them — the firm may believe stored retain samples satisfy release requirements, when FDA's request makes clear they do not. Strong inference
  • An import alert blocks all products from the facility, not just the failing batches — revenue loss extends to any compliant product the firm also makes there. FDA-stated
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use Finished-batch release testing completeness rate — Flag if: Any batch released without both results on file triggers immediate stop-use of that batch. Daily Production Meeting
  • Stop-Use In-house component identity testing rate — Flag if: Any component lot used in production without an in-house identity test result triggers quarantine of all product made from that lot. Daily Production Meeting
  • Escalate Supplier qualification coverage rate — Flag if: Any active supplier without a current qualification package triggers suspension of material use from that supplier. Quality Review Board
  • Escalate Stability program coverage rate — Flag if: Any marketed product without an active stability time-point in the past 12 months triggers escalation to QU Director within 5 business days. Quality Review Board
  • Escalate Warning-letter CAPA effectiveness check rate — Flag if: Any CAPA without a documented effectiveness check by its locked 90-day date triggers escalation to site leadership and the CGMP consultant. Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • Finished Drug Product Release SOP: Confirm the SOP requires a signed laboratory assay result AND a signed microbiological test result in the batch record before any lot-disposition decision is made. (21 CFR 211.165(a) and 211.165(b))
  • Incoming Component Testing SOP: Confirm the SOP requires at least one in-house specific identity test for every incoming component lot, independent of any supplier COA. (21 CFR 211.84(d)(1))
  • Supplier Qualification and COA Validation SOP: Confirm the SOP defines a periodic re-validation interval for each component supplier and requires independent testing data to support that validation — not COA review alone. (21 CFR 211.84(d)(2))
  • Stability Program SOP: Confirm the SOP requires a stability protocol and active sample pull schedule for every marketed drug product, with defined time points and acceptance criteria, before product launch. (21 CFR 211.166(a))
Also listed in Drugs & Biologics
Listed
Amgen Inc.
Drug · Thousand Oaks, CA · The Office of Prescription Drug Promotion (OPDP)
FDA cited: Drug Product/Misbranded, False & Misleading Claims. See the linked letter for details.
Indexed for completeness — not given a floor-action deep dive this week. FDA letter →
Listed
Calibrate IV Hydration
Biologic · Center for Biologics Evaluation and Research (CBER)
FDA cited: Unapproved New Drugs/Unlicensed Biological Product Violations. See the linked letter for details.
Indexed for completeness — not given a floor-action deep dive this week. FDA letter →
Listed
Beaute Bounty
Biologic · Center for Biologics Evaluation and Research (CBER)
FDA cited: Unapproved New Drugs/Unlicensed Biological Product Violations. See the linked letter for details.
Indexed for completeness — not given a floor-action deep dive this week. FDA letter →
Listed
Best Chinese Medicines LLC
Drug · Center for Drug Evaluation and Research (CDER)
FDA cited: Unapproved New Drugs. See the linked letter for details.
Indexed for completeness — not given a floor-action deep dive this week. FDA letter →
Food
2 letters detailed in full
Critical
Rama Food Manufacture Corp.
Food · Ontario, California · Human Foods Program · Posted 10/27/2026 · Issued 09/22/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA determined RTE rice noodle products from both Ontario, CA facilities are adulterated under 21 U.S.C. § 342(a)(4).
  • FDA lab confirmed all three finished product types had pH values supporting L. monocytogenes growth; one also supported C. botulinum growth.
  • The S Parco Avenue facility had no food safety plan — all seven required elements were absent.
  • FDA measured finished product temperatures as high as 82°F during production; one pallet cooled only 4.5°F over 26 hours in refrigeration.
  • Two validation studies promised in the FDA-483 response had not been submitted to the Agency as of the warning letter date.
✅ Here's what you need to check for
  • ☐ Does your RTE food facility have a written food safety plan with all seven required elements: hazard analysis, preventive controls, supply-chain program, recall plan, monitoring procedures, corrective action procedures, and verification procedures?
    If you can't confirm this: Stop distribution of affected products immediately. Quarantine any lots produced without a compliant food safety plan. Engage a qualified food safety consultant to develop and implement all required plan elements before resuming production. Open a CAPA with the Quality Manager as owner, due within 30 days.
  • ☐ Do your process preventive controls set time and temperature limits that keep RTE products below 70°F at all in-process and cooling stages — and do you have monitoring records showing these limits are actually met every production day?
    If you can't confirm this: Hold all in-process and finished product lots that lack compliant temperature monitoring records. Verify current cooler capacity against actual product load. Add data-logger monitoring at every cooling stage and set a maximum 3-hour cumulative exposure limit above 70°F for applicable products. Assign the Food Safety Manager as CAPA owner, due within 14 days.
  • ☐ Does your facility verify that finished RTE products consistently meet their pH critical limit — and do you test a number of samples representative of the entire lot, not just a single sample?
    If you can't confirm this: Hold any lot where pH testing was not representative of the full batch. Increase the number of pH measurements per lot to cover the full production run. Review all distributed lots tested only with a single sample and conduct a retrospective risk assessment. Notify your QA Director within 24 hours.
  • ☐ Is all food-contact equipment — including cutting machines, noodle trays, cut tables, and any sheets in direct contact with RTE product — cleaned and sanitized at a frequency adequate for daily RTE production?
    If you can't confirm this: Stop using any food-contact surface that has not been cleaned today. Sanitize all food-contact surfaces before the next production run. Rewrite your master sanitation schedule to require daily cleaning of all food-contact surfaces used in RTE production. Assign the Sanitation Supervisor as owner, due immediately.
  • ☐ Does your environmental monitoring program (EMP) include swabbing for Listeria species in RTE production and post-process areas — and do you have a written corrective action procedure triggered when any Listeria species is found?
    If you can't confirm this: If you lack a written EMP or corrective action procedure for Listeria, quarantine product produced since the last confirmed clean environmental result. Engage a food safety microbiologist to design a zone-based Listeria EMP. Document and implement corrective action procedures for positive findings before resuming RTE production. Open a CAPA with the QA Manager as owner, due within 21 days.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): This letter's core failure — no hazard analysis and no validated process controls for a known biological hazard — maps directly to OSD process validation gaps. Confirm your process validation protocol identifies all known microbiological risks for each product family and that each critical process parameter has a validated range with monitoring records. Verify your master batch record requires documented temperature and humidity readings at each processing step. Rule: 21 CFR 211.113.
  • Topical / semisolid / liquid: The failure to control bioburden and environmental pathogens in post-process RTE food parallels purified-water system bioburden and open-vessel hold-time risks in topical manufacturing. Confirm your water system loop sanitization cadence and bioburden/endotoxin test results are within specification before each batch. Verify that open-vessel hold times for aqueous or water-miscible products are defined, monitored, and recorded, and that your EMP includes B. cepacia-specific testing for aqueous topical products. Rule: 21 CFR 211.113; USP <61>/<62>.
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • Post-cook cooling area and refrigerator/cooler storage — Watch whether cooked RTE product is placed directly into stacked pallets or cases before it reaches a safe temperature. Look for data loggers or thermometers actively recording product temperature during cooling. Check whether finished packaged product in the cooler shows condensate inside packaging — a sign it was warm when sealed.
  • Cutting, tray, and food-contact surface area — Look for any food-contact surface — cutting tables, trays, sheets in direct product contact — that shows food residue, discoloration, or frayed edges. Ask to see today's cleaning log and confirm every surface used today has a cleaning entry with time and sanitizer concentration. Watch whether drying or curing sheets are included in the cleaning schedule.
  • Packaging and finished product staging area — Watch how finished RTE products are staged before entering the cooler. Check whether any pallet sits at ambient temperature after packaging. Verify that temperature checks of finished product in the cooler are actually documented on a per-lot basis, not just spot-checked occasionally.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your Production / RTE Processing supervisor
  • Ask: After noodles finish cooking, what happens to them before they go in the cooler? How long do they sit out, and does anyone check the temperature during that time? RTE food — cooked / post-process cooling only
    🚩 Flag if you hear: Operators describe product sitting at room temperature for more than a short period without temperature monitoring.
    → Then: Hold the batch now; tell QA on call; open a deviation today.
Hand to your Sanitation supervisor
  • Ask: Which food-contact surfaces did you clean today, and which ones are on a rotating schedule — meaning they were NOT cleaned today? Walk me through what you cleaned this shift.
    🚩 Flag if you hear: Any food-contact surface used in RTE production today was not cleaned today.
    → Then: Hold the batch now; tell QA on call; open a deviation today.
Hand to your QC / Food Safety supervisor
  • Ask: When you check the pH of a finished lot, how many samples do you pull? Is that number written down somewhere in the food safety plan, and did you meet it for every lot today? RTE food — pH-controlled products only
    🚩 Flag if you hear: Fewer samples were tested than the food safety plan requires, or any sample exceeded the pH critical limit.
    → Then: Hold the batch now; tell QA on call; open a deviation today.
Hand to your QA supervisor
  • Ask: When was the last time we swabbed for Listeria in the post-cook and packaging areas? What happened with the results — were any corrective actions opened, and are they all closed?
    🚩 Flag if you hear: Last swabbing was more than one month ago, or any Listeria-positive corrective action is still open past its due date.
    → Then: Hold the batch now; tell QA on call; open a deviation today.
Hand to your Warehouse / Materials supervisor
  • Ask: When finished product goes into the cooler, does anyone record the product temperature at the time it goes in — and again after several hours? Where do those records go? RTE food — refrigerated finished product storage only
    🚩 Flag if you hear: No temperature is recorded when product enters the cooler, or records show product temperatures above 41°F after several hours of storage.
    → Then: Hold the batch now; tell QA on call; open a deviation today.
💡 Things you may not have thought of
  • Using pH alone as the primary Listeria control in a high-water-activity RTE product with demonstrated cooling failures creates compounding risk — neither hurdle is reliably in place. Strong inference
  • Transferring insufficiently cooled product between facilities — wrapping pallets in plastic before the product is cool — can trap heat and extend the time product stays in the pathogen growth temperature range during transit. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use RTE lot temp-record compliance rate — daily — Flag if: Any single lot missing a temperature record or exceeding the cumulative time-above-70°F critical limit Daily Production Meeting
  • Stop-Use Finished lot pH compliance rate — daily — Flag if: Any lot where sample count is below plan-required minimum, or any individual pH measurement exceeds the critical limit Daily Production Meeting
  • Stop-Use Open Listeria EM corrective actions — overdue count — Flag if: Any Listeria-positive EM result without a closed corrective action within the EMP-defined response window Quality Review Board
  • Escalate Daily food-contact surface sanitation completion rate — Flag if: Any food-contact surface used in RTE production not cleaned and sanitized on the same day it was used Daily Production Meeting
  • Escalate FDA CAPA commitment on-time completion rate — Flag if: Any CAPA item not completed and submitted to FDA by its original committed date Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • Food Safety Plan — Process Preventive Controls section: Confirm the plan sets a maximum cumulative time-above-70°F limit for all in-process RTE product stages, with a monitoring frequency that detects exceedances the same shift they occur. (21 CFR 117.135(c)(1); 21 CFR 117.145(a))
  • Master Sanitation Schedule (MSS): Confirm the MSS requires daily cleaning and sanitization of every food-contact surface used in RTE production — including drying or curing sheets — and lists the sanitizer, concentration, and contact time. (21 CFR 117.135(c)(3))
  • Environmental Monitoring Program (EMP): Confirm the EMP includes a written corrective action procedure triggered by any Listeria-positive swab result, specifying the response timeframe, zone expansion rules, and product disposition authority. (21 CFR 117.165(b))
  • Finished Product Release Procedure: Confirm the release procedure requires documented pH and temperature verification for every lot, with the minimum required number of samples specified and locked — and that no lot is released until both criteria are confirmed met. (21 CFR 117.135(c)(1); 21 CFR 117.145(a))
Moderate
Global Imports Origins
Carried over listed in an earlier issue
Food · Houston, TX · Office of Inspections and Investigations · Posted 06/23/2026 · Issued 04/23/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA found Global Imports Origins had no FSVP at all for Red Pepper (Mixed Vegetables) from a redacted supplier.
  • The firm did not respond to the Form FDA 483a issued March 12, 2026.
  • FDA warned it may refuse admission of the firm's imports and pursue DWPE under Import Alert 99-41.
  • FDA inspected the firm previously on April 17–May 5, 2023, establishing a prior compliance review.
  • FDA stated the violation list is not all-inclusive; other imported products may also be at risk.
✅ Here's what you need to check for
  • ☐ Do you import any human or animal food into the US? If yes, do you have a written FSVP on file for every supplier and every product you import?
    If you can't confirm this: Stop importing any product that lacks a completed, documented FSVP. Quarantine those shipments pending review. Assign a qualified person to draft the missing FSVPs immediately and do not release held inventory until plans are in place.
  • ☐ Did you receive an FDA Form 483a or 483 for FSVP violations at any inspection in the past three years? If yes, did you submit a written response within 15 working days?
    If you can't confirm this: If a response was not sent, draft and send one now — even late. Include your root cause, corrective actions, and a copy of any FSVP you developed. Contact the named FDA compliance officer in the letter.
  • ☐ For each foreign supplier you use, do your records show a completed hazard analysis and a supplier verification activity (such as an audit or test results) within the required timeframe?
    If you can't confirm this: Pull your supplier list. For any supplier missing a completed hazard analysis or verification record, open a CAPA with a named owner and a 30-day due date to complete or obtain those records before the next import shipment.
  • ☐ Is your FSVP document reviewed and updated whenever you add a new supplier or product, or when you learn of a new food safety risk from an existing supplier?
    If you can't confirm this: Add a change-control step to your import onboarding procedure. Require a dated FSVP review before the first purchase order is issued to any new supplier. Assign a single owner role responsible for that review.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): If you use foreign-sourced excipients or active ingredients, confirm each supplier has a completed supplier qualification file — including a hazard or risk assessment and a recent audit or test result — before the next purchase order. Check 21 CFR 211.84 for incoming component testing requirements and confirm your supplier qualification SOP requires completion before first use.
  • Topical / semisolid / liquid: If you source water-phase ingredients, preservatives, or raw materials from foreign suppliers, confirm each has a completed supplier qualification record with a documented risk assessment and a verification activity on file. For aqueous products, also confirm raw-material microbial limits and certificates of analysis are reviewed per lot before use. Rule: 21 CFR 211.84.
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • Import receiving dock or warehouse area where foreign food shipments arrive — Check whether any incoming shipment has a matching FSVP document pulled and reviewed before the product is accepted. If staff accept shipments without checking an FSVP binder or system record, the plan is not being followed in practice.
  • Office or file area where import compliance records are kept — Look for a physical or electronic FSVP file for each active supplier. If files are missing, incomplete, or undated, the program is not documented. Check whether hazard analyses and supplier verification records (audits, test results, certifications) are present for every supplier.
  • Purchasing or procurement workstation where new supplier orders are placed — Observe whether a completed FSVP is required before a purchase order is issued to a new foreign supplier. If staff can place an order without an FSVP sign-off step, the onboarding control is missing.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your Warehouse / Materials supervisor
  • Ask: When a new shipment arrives from a foreign supplier, what paperwork do you check before accepting it? Do you ever check anything called an FSVP?
    🚩 Flag if you hear: Operator cannot name an FSVP check step or says shipments are accepted without any supplier safety review.
    → Then: Hold the shipment now; tell QA on call; open a deviation today.
  • Ask: Has any foreign supplier changed recently — new country, new product, or new contact? Did anything change in how we approved them?
    🚩 Flag if you hear: A supplier change happened and no updated FSVP review was done.
    → Then: Hold new orders from that supplier; tell QA on call; open a deviation today.
Hand to your QA supervisor
  • Ask: When we get a letter or form from FDA, who is responsible for sending a written response? Do we have a deadline we follow?
    🚩 Flag if you hear: No named owner or no deadline is known; or a past FDA letter went unanswered.
    → Then: Escalate to QA on call immediately; identify any unanswered FDA communications today.
  • Ask: Can you show me the FSVP file for our top three foreign suppliers right now? Is each one complete with a hazard analysis and a recent supplier check?
    🚩 Flag if you hear: Any FSVP file is missing, incomplete, or has no dated supplier verification record.
    → Then: Hold imports from that supplier; tell QA on call; open a CAPA today.
💡 Things you may not have thought of
  • An FSVP gap for one named product likely signals similar gaps for other suppliers the firm imports from — FDA's own language confirms this risk. Strong inference
  • Silence after a 483a accelerates FDA's escalation timeline; non-response is itself a compliance signal FDA weighs in enforcement decisions. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use Active SKUs with completed FSVP on file (%) — Flag if: Any active imported SKU without a completed FSVP before its next shipment. Quality Review Board
  • Escalate Suppliers with current hazard analysis and verification (count) — Flag if: Any active supplier with missing hazard analysis or expired/missing verification activity. Quality Review Board
  • Escalate FDA 483a response submitted within 15 working days (days) — Flag if: Response not submitted by working day 15 from confirmed receipt. Daily Production Meeting
  • Escalate New suppliers with FSVP completed before first PO (%) — Flag if: Any new supplier onboarded without completed FSVP before first PO. Quality Review Board
  • Escalate Overdue FSVP CAPAs without effectiveness check (count) — Flag if: Any FSVP CAPA overdue against its original due date, or closed without an independent effectiveness check. Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • FSVP Master Procedure: Confirm the SOP requires a completed FSVP document before any new foreign-sourced food product is imported for the first time. (21 CFR 1.502(a))
  • Supplier Onboarding / Qualification Procedure: Confirm the procedure requires a documented hazard analysis and at least one supplier verification activity for every new foreign food supplier before the first purchase order is issued. (21 CFR 1.505)
  • FDA Correspondence Response Procedure: Confirm the SOP sets a 15-working-day deadline for submitting a written response to any FDA Form 483a or warning letter, with a named owner responsible for drafting and sending the response. (21 CFR part 1, subpart L)
  • FSVP Periodic Review Procedure: Confirm the SOP requires a documented review of each FSVP when a new food safety risk is identified for a supplier or when a supplier's status changes, with a dated sign-off. (21 CFR 1.508)
Medical Devices
2 letters detailed in full
Critical
Peter Schiff Enterprises
Device · Cookeville, TN · Center for Devices and Radiological Health · Posted 10/27/2026 · Issued 08/26/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA found Models 305L, 306L, and 310C are distributed without PMA or 510(k) clearance — both are required.
  • FDA cited four repeat observations spanning 2011, 2013, and 2017 inspections; all firm responses found not adequate.
  • Non-medical-grade materials labeled 'Not for internal or medical use' contact cardiac devices; no biocompatibility testing done.
  • FDA stated failure during open-heart surgery could result in serious harm to critically ill and pediatric patients.
  • Wires from rejected electrode pads are routinely cut and reused without documentation, approval, or verification.
✅ Here's what you need to check for
  • ☐ Do all your marketed medical devices have current FDA clearance (510(k)), approval (PMA), or a confirmed exemption — and have any design changes been assessed against the regulatory threshold for a new submission?
    If you can't confirm this: Stop distributing the affected device immediately. Quarantine inventory. Engage a regulatory counsel to conduct a 510(k)/PMA gap analysis and assess whether cumulative design changes require a new submission before any further distribution.
  • ☐ Are all materials and components that contact your device or patient — including cleaning agents, adhesives, coatings, and wires — medical-grade and covered by a completed biocompatibility assessment per ISO 10993-1?
    If you can't confirm this: Hold production and distribution of affected device lots. Identify every non-medical-grade material in direct or indirect contact with the device or patient. Commission a biocompatibility risk assessment immediately, and do not release product until assessment is complete and reviewed by QA.
  • ☐ Are customer complaints — including informal 'feedback' about device performance — captured in your complaint handling system, evaluated for MDR reportability, and investigated per a written procedure?
    If you can't confirm this: Open a CAPA with your QA Director as owner, due within 30 days. Retroactively review all informal feedback for the past 24 months. Document and assess each instance for MDR reportability. Update your written complaint procedure to include all required elements under 21 CFR 820.198(a).
  • ☐ Has your firm conducted internal quality audits on a documented schedule, with auditors who do not have direct responsibility for the areas being audited?
    If you can't confirm this: Assign a qualified auditor — internal or external — who is independent of the areas being audited. Schedule and complete a full system audit within 60 days. Document audit criteria, frequency, and re-audit provisions in your Quality Manual. Open a CAPA tracked by QA.
  • ☐ Are nonconforming product dispositions — including any rework — fully documented, evaluated, approved by authorized personnel, and verified before return to production?
    If you can't confirm this: Quarantine all product with undocumented or unapproved rework. Review production records for the past 24 months for nonconforming units. Establish a written nonconformance procedure with disposition, investigation, and rework verification requirements before releasing quarantined product.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): Supplier qualification gaps apply directly. Confirm every excipient and cleaning agent has a qualified supplier, documented specifications, and incoming acceptance testing before use in production. Confirm your nonconformance procedure requires authorized disposition for every rejected unit before the next batch starts. Rule: 21 CFR 211.84; 21 CFR 211.192.
  • Topical / semisolid / liquid: Non-medical-grade or unqualified materials in direct product contact are a direct contamination risk. Confirm all preservatives, emulsifiers, and water sources meet USP or compendial grade, have supplier qualification records, and are tested per acceptance criteria before use. Confirm bioburden and microbial limits testing is performed per USP <61>/<62> on each lot. Rule: 21 CFR 211.84; 211.67.
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • Incoming materials receiving and storage area — Look for cleaning agents, adhesives, silicone, or wire materials sourced from retail or home improvement stores. Check whether any material container or SDS states 'not for medical use,' 'industrial,' or 'not for internal use.' Check whether any material lacks a supplier qualification record or acceptance criteria document.
  • Production floor — electrode pad assembly and rework area — Watch whether operators cut wires from rejected pads and set them aside for reuse. Check whether a rework log exists at the workstation. Confirm whether rejected units are physically segregated and labeled, and whether any unit moves back to production without a signed disposition and verification record.
  • Quality records room or DHR file area — Pull the device history record for the most recently released lot. Confirm it contains: QA release signature, label examination record with date and name, and documentation of every manufacturing step including continuity check, cleaning, and packaging. Check whether the lot number is unique and sequential.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your QA supervisor
  • Ask: When a customer calls or emails about a device problem — even just to say it didn't work right — what do you do with that information? Walk me through it step by step.
    🚩 Flag if you hear: Operator says they tell the owner verbally, log it informally, or do nothing unless it seems serious.
    → Then: Hold any undocumented complaint; tell QA on call; open a deviation today.
  • Ask: When we reject a unit on the production floor, what happens to it next? Can you show me the last rejected unit's paperwork?
    🚩 Flag if you hear: Operator cannot produce a disposition record, or says parts are set aside for reuse without any paperwork.
    → Then: Quarantine all units lacking disposition records; tell QA on call; open a deviation today.
  • Ask: Before we ship a finished lot, what steps does QC sign off on? What happens if any step in the device history record isn't documented as done?
    🚩 Flag if you hear: Operator says QC does not review every step, or that lots have shipped with blank fields in the DHR.
    → Then: Hold the lot; tell QA on call; open a deviation today.
Hand to your Warehouse / Materials supervisor
  • Ask: When we get a new batch of materials — cleaning supplies, wire, adhesives, anything — do we check them against a spec before using them? What does that check look like?
    🚩 Flag if you hear: Operator says there is no incoming check, or that materials come straight from a retail store to the production floor.
    → Then: Quarantine the incoming material lot; tell QA on call; open a deviation today.
💡 Things you may not have thought of
  • Repeat findings across four inspection cycles signal the quality unit lacks authority to drive change — procedural fixes alone will not close this gap without structural leadership intervention. Strong inference
  • Undocumented rework of rejected components means the traceability of distributed devices is broken — a retrospective field assessment may be needed to scope patient exposure. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use Biocompatibility clearance rate per released lot — Flag if: Any lot falls below 100% biocompatibility clearance at time of release. Daily Production Meeting
  • Stop-Use 510(k)/PMA submission milestone on-time rate — Flag if: 513(g) not submitted within 30 days of FDA response deadline, OR 510(k)/PMA not filed by committed milestone date. Quality Review Board
  • Stop-Use Nonconforming unit disposition completeness rate — Flag if: Any nonconforming unit from the current or prior lot lacks complete disposition documentation before the next lot starts. Daily Production Meeting
  • Escalate Complaint capture and MDR evaluation rate — Flag if: Any customer contact not logged and MDR-evaluated within 5 business days. Daily Production Meeting
  • Escalate Internal audit schedule adherence and CAPA effectiveness rate — Flag if: Audit not completed by committed date, OR fewer than 100% of audit findings have effectiveness verification at 90-day check. Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • Purchasing Controls Procedure: Confirm the procedure defines supplier qualification steps, requires quality agreements with all suppliers, and sets acceptance criteria for every direct-contact material before use in production. (21 CFR 820.50)
  • Complaint Handling Procedure: Confirm the procedure defines 'complaint' per 21 CFR 820.3(b), requires MDR reportability evaluation for every complaint, and lists all required investigation record elements including UDI, complainant contact, and corrective action taken. (21 CFR 820.198(a); 21 CFR 803.17)
  • Nonconforming Product and Rework Procedure: Confirm the procedure requires documented disposition by authorized personnel for every nonconforming unit, requires written approval and post-rework verification before return to production, and prohibits undocumented component reuse. (21 CFR 820.90(a))
  • Internal Audit Procedure: Confirm the procedure sets a defined audit frequency, requires auditors to be independent of the areas audited, includes audit criteria, and requires re-audit provisions when findings are not closed effectively. (21 CFR 820.22)
Critical
Olympus Medical Systems Corporation
Carried over listed in an earlier issue
Device · Hachioji-shi, Tokyo, Japan · Center for Devices and Radiological Health · Posted 10/20/2026 · Issued 10/07/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA found devices from all six inspected Olympus facilities are adulterated under section 501(h) of the Act.
  • A confirmed patient death and Class I recall of UHI-4 insufflators occurred in 2023; catastrophic hazards were still absent from risk management files at the November 2025 inspection.
  • A patient death was reported during explant surgery for a detached Vizishot 2 FLEX needle; the firm changed the manufacturing date during rework to circumvent an active ship hold.
  • FDA found the adequacy of the firm's response cannot be determined for every major violation across all six facilities after five rounds of responses.
  • Active Class I recalls or removal actions cover at least five product families across three facilities.
✅ Here's what you need to check for
  • ☐ Do your risk management files for each active device reflect ALL known catastrophic hazards — including those found in complaint investigations and MDRs — with documented risk control measures?
    If you can't confirm this: Quarantine and suspend distribution of any device where the risk management file has not been updated to reflect known serious harms. Open a CAPA immediately, assign a risk management owner, and update all affected files before any further release.
  • ☐ Are all IFU compatibility claims for your devices — for accessories, lasers, or third-party components — supported by completed design validation testing under actual use conditions?
    If you can't confirm this: Stop distributing any device where an IFU claims compatibility that has not been validated. Conduct a retrospective review of all compatibility claims across your portfolio. Document findings and open a CAPA with a named owner and a 30-day due date for each unsupported claim.
  • ☐ Are all active ship holds, quarantines, and nonconformance records controlled so that no rework or manufacturing date change can bypass them without QA sign-off?
    If you can't confirm this: Audit your nonconformance management system now. Confirm that manufacturing date fields are locked after a ship hold is placed. If any lot was released by changing a date during an active hold, initiate a field-safety assessment and notify your quality director within one shift.
  • ☐ Are heat sealing processes for all sterile barrier packaging validated at the actual production setpoints — not just nominal settings — and is that validation current on the equipment currently in use?
    If you can't confirm this: Place a hold on any sterile packaged product whose sealing process was validated only at nominal settings or on decommissioned equipment. Conduct a health hazard assessment for distributed lots. Do not release new product until revalidation at actual setpoints is complete.
  • ☐ Do design traceability matrices exist for all active product families, linking every design requirement — including safety requirements — to verified and validated test evidence?
    If you can't confirm this: Stop releasing design changes for any product without a completed traceability matrix. Open a CAPA with a named design owner for each product family lacking one, and set a 60-day completion deadline.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): The IFU compatibility-claim finding translates to labeling claims for OSD products — confirm every label claim about equipment compatibility (e.g., tablet presses, coaters, blister sealers) is supported by validation data. Confirm cleaning-validation worst-case matches the actual changeover order and campaign length you run — not an idealized sequence. Metric to watch: count of label claims lacking a linked validation record. Rule: 21 CFR 820.30(g) / 21 CFR 211.68.
  • Topical / semisolid / liquid: The sterile barrier sealing gap translates to container-closure integrity for liquid and semisolid products — confirm that container-closure integrity testing (CCIT) was performed on the specific filling and sealing equipment currently in use, at actual production settings, not nominal or legacy validated settings. If a sealer or filler was decommissioned and replaced, confirm that revalidation was completed on the replacement equipment before product release. Metric to watch: percent of active container-closure validation records linked to currently installed equipment serial numbers. Rule: 21 CFR 820.75(a) / 21 CFR 211.94.
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • Sterile barrier sealing / packaging line — Confirm the sealer's displayed setpoints (temperature, pressure, time) match the validated production setpoints in the current validation report — not the nominal or test setpoints. Check that the validation was run on this specific sealer serial number, not a decommissioned unit.
  • Nonconformance and ship-hold control station (warehouse / ERP terminal) — Observe how a ship-hold lot is handled during rework. Confirm that the manufacturing date, lot number, and quantity fields are locked and that any change requires a QA co-signature before the system accepts it. Look for any workaround that allows a held lot to move without QA approval.
  • Design / risk management document archive — Pull the risk management file for any device that has had an MDR or complaint in the last 12 months. Confirm that every hazard identified in those MDRs and complaints is listed in the risk management report with a documented risk control measure. Note any hazard present in the complaint record but absent from the risk file.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your QA supervisor
  • Ask: When a complaint investigation or CAPA test shows a device failed a specification, what do you do next — and how fast is an NCR opened?
    🚩 Flag if you hear: Operators describe waiting for a trend, a manager decision, or CAPA closure before opening an NCR for a test failure.
    → Then: Hold the investigation lot; tell QA on call; open a deviation today.
  • Ask: If a lot is under a ship hold right now, what stops someone from changing the manufacturing date or lot number in the system?
    🚩 Flag if you hear: No system lock or co-signature requirement is described; staff are unsure who controls the hold fields.
    → Then: Freeze all held lot records immediately; tell QA on call; open a deviation today.
  • Ask: For any device your team makes that lists an accessory or energy-source compatibility in the IFU — do you know if design validation was run for that specific claim?
    🚩 Flag if you hear: Staff cannot point to a validation report for a specific IFU compatibility claim.
    → Then: Flag the device to QA on call; suspend IFU-claim review until evidence is confirmed; open a CAPA today.
  • Ask: When a CAPA or NCR is closed, who confirms it actually worked — and does that check happen at 90 days and 180 days with documented evidence?
    🚩 Flag if you hear: No effectiveness check is scheduled, or checks are done by the same person who wrote the CAPA.
    → Then: Tell QA on call; audit closed CAPAs from the last 18 months for missing effectiveness checks; open a deviation today.
Hand to your QC / Micro Lab supervisor
  • Ask: When the last sterile barrier seal test was run, did the setpoints on the sealer match exactly what is in the current validation report — and was that validation done on this specific sealer? Sterile / terminal-sterilized device packaging only
    🚩 Flag if you hear: Operators describe nominal settings, a different sealer serial number, or no validation report on file for the current equipment.
    → Then: Hold packaged product from that sealer; tell QA on call; open a deviation today.
💡 Things you may not have thought of
  • A multi-cycle pattern of 'adequacy cannot be determined' responses signals FDA may move to enforcement without further response opportunities, regardless of ongoing CAPA activity. Strong inference
  • Circumventing a ship hold by changing manufacturing dates creates a data integrity finding layered on top of the product-safety event, which independently triggers heightened FDA scrutiny. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use Risk file completeness vs. MDR/complaint hazards — all devices — Flag if: Any device family below 100% confirmed, or any new MDR/complaint hazard not reflected within 5 business days of identification. Quality Review Board
  • Stop-Use Unsupported IFU compatibility claims — portfolio-wide count — Flag if: Any unsupported IFU compatibility claim identified. Quality Review Board
  • Stop-Use Sterile barrier sealing validation complete on active sealers — % current — Flag if: Any sealer/product combination without a completed, passing validation at actual setpoints. Quality Review Board
  • Stop-Use Unauthorized modifications to ship-hold records — count — Flag if: Any single record modification without prior QA signature. Daily Production Meeting
  • Escalate NCR opened within 1 day of in-investigation test failure — Flag if: Any test failure without an NCR opened within 1 business day. Daily Production Meeting
  • Escalate CAPA effectiveness check rate at 90 and 180 days post-closure — Flag if: Any CAPA missing a 90-day or 180-day effectiveness check, or any check that finds recurrence. Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • Risk Management procedure / Risk Management Report template: Confirm the procedure requires mandatory update of the risk management file within a defined timeframe (e.g., 5 business days) whenever a complaint investigation or MDR analysis identifies a new hazard or higher severity than previously documented. (21 CFR 820.30(g))
  • Design Change Control / Design Validation procedure: Confirm the procedure requires completed design validation under actual or worst-case use conditions before any IFU compatibility claim is added, and that a traceability matrix linking each claim to validation evidence is required for all active device families. (21 CFR 820.30(g))
  • Global Nonconformance Management procedure (e.g., GSOP-00022 or equivalent): Confirm the procedure prohibits modification of any field in an active NCR or ship-hold record (including manufacturing date and lot number) without a prior, documented QA co-signature, and that the system audit trail is subject to independent second-person review on a defined schedule. (21 CFR 820.90(a))
  • Process Validation / Sterile Barrier Sealing Validation procedure: Confirm the procedure requires that process validation is performed on the specific equipment serial number currently in production, that equipment equivalency requires documented testing justification beyond same manufacturer and model number, and that validation must pass at both high and low challenge setpoints — not only nominal settings. (21 CFR 820.75(a))
This is one agent. Here's what else it does for your team.
You're reading the FDA edition. The same engine reads the rest of your regulatory world — and puts your people through the failures before they happen.
Other agencies, same brief. OSHA, EPA, and seven more agencies, on the same cadence — one view of your site's whole regulatory exposure. See the agencies we cover →
An agent pointed at your own site. We build a private version that reads your inspection history, 483s, and internal signals — not just public letters. Your data stays segregated, is never used to train shared models, and the system ships with a CSA-style validation rationale for your quality file. Ask about a private agent →
Put your team in the drill. Timed crisis-simulation software your leads run on a clock, without an outside facilitator. First scenario: a wildfire plant shutdown, built from a real one; further scenarios in development. Preview the crisis sim →
Forward this to the one person on your quality team who should be reading it. New sectors ship first to current subscribers.
PharmTech.AI by Aligned Executive Solutions, Inc. · Former FDA-inspected QA leadership · cGMP & quality systems
Report verified for accuracy by PharmTech.AI.
AI-generated with human-in-the-loop review, from public FDA Warning Letters — each letter linked to its FDA source. FDA-stated facts are kept separate from clearly labeled PharmTech.AI interpretation; product identifications for redacted letters are inferences with confidence + basis, not FDA findings. Warning letters may be rescinded or closed out — verify current status at fda.gov before relying on this. Corrections: mike@aesresults.com. Informational thought-leadership, not legal or regulatory advice.
PharmTech.AI™ is a trademark of Aligned Executive Solutions, Inc. All other names and marks are the property of their respective owners.
© 2026. All rights reserved.